Samsung Bioepis announced on Wednesday that it has initiated a comprehensive artificial intelligence training program aimed at enhancing expertise within the biopharmaceutical sector. This initiative represents the company’s inaugural effort to integrate AI as a fundamental capability across its operations, thereby improving overall efficiency.
The newly established training center, known as the AI Academy, is located at Samsung Bioepis’ headquarters in Songdo, Incheon. The program is designed to accommodate approximately 1,000 employees, each required to complete a minimum of seven hours of training that blends theoretical knowledge with practical application. The curriculum will encompass the utilization of generative AI tools, development of job-specific models, and automation of workflows.
To bolster its capabilities further, Samsung Bioepis plans to assemble a dedicated task force led by its AI team. This group will be responsible for developing customized AI agents tailored to the specific needs of each division within the company. The strategic focus is to not only enhance operational effectiveness but also to ensure that each department can leverage AI technology to its fullest potential.
In addition to the training program, Samsung Bioepis is expanding its broader initiatives in AI and digital innovation. This includes the implementation of digital twin technology to expedite the drug development process, building a secure in-house AI infrastructure, and forming collaborations with external partners to explore AI-driven drug candidates.
Kang Dae-sung, head of the people team at Samsung Bioepis, emphasized the importance of this initiative, stating, “As AI becomes a key driver of global competitiveness in biopharma, we will continue to strengthen our capabilities to enhance the company’s core competitiveness.” This underscores the strategic importance that AI holds for the future of the biopharmaceutical industry.
As the biopharmaceutical landscape becomes increasingly competitive, Samsung Bioepis is positioning itself to lead in adopting cutting-edge technologies. The integration of AI training not only equips employees with essential skills but also aligns with the industry’s shift towards data-driven decision-making processes. By fostering a culture of innovation through AI, the company aims to streamline operations and enhance the quality of its drug development efforts.
The launch of the AI Academy and the accompanying training initiatives signal a forward-looking approach by Samsung Bioepis, reflecting a broader trend within the biopharmaceutical sector to embrace technological advancements. As companies strive to remain competitive, the focus on developing AI capabilities may well define the future landscape of drug development and operational efficiency.
See also
Sam Altman Praises ChatGPT for Improved Em Dash Handling
AI Country Song Fails to Top Billboard Chart Amid Viral Buzz
GPT-5.1 and Claude 4.5 Sonnet Personality Showdown: A Comprehensive Test
Rethink Your Presentations with OnlyOffice: A Free PowerPoint Alternative
OpenAI Enhances ChatGPT with Em-Dash Personalization Feature
